Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

Bravecto One 100 mg Tablet (Chewable) is a Health Canada–registered veterinary drug (DIN 02502224) held by Intervet Canada Corp, containing Fluralaner. Health Canada lists its status as Marketed (status date 05 Apr 2021). Nexara Health has matched 57 registrations of Fluralaner across 8 other regulated markets, 3 of them in the same strength and dosage form.

Health Canada registration

DIN02502224
Brand nameBravecto One
Active ingredientFluralaner
Strength100 mg
Dosage formTablet (Chewable)
RouteOral
CompanyIntervet Canada Corp
StatusMarketed — 05 Apr 2021
ClassVeterinary
ATC
AHFS
Regulator recordHealth Canada DPD entry · Product monograph

Fluralaner registered in other markets

57 registrations of the same molecule in 8 national registries outside Canada (first 33 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.

CountryProductMarketing authorisation holderStrengthFormStatusRegistry
DenmarkFluralaner IntervetIntervet International B.V.100 mgtyggetabletterCentralLaegemiddelstyrelsen
FinlandFluralaner IntervetIntervet International B.V.100 mgpurutablettiMyyntilupa myönnettyFimea Perusrekisteri
PolandFluralaner IntervetIntervet International B.V.560 mgTabletka do rozgryzania i żuciaBezterminoweURPL RPL
DenmarkBravectoIntervet International B.V.250 mgtyggetabletterCentralLaegemiddelstyrelsen
DenmarkBravectoIntervet International B.V.150 mg/mlpulver og solvens til injektionsvæske, suspensionCentralLaegemiddelstyrelsen
DenmarkBravectoIntervet International B.V.112,5 mgtyggetabletterCentralLaegemiddelstyrelsen
DenmarkBravectoIntervet International B.V.1000 mgtyggetabletterCentralLaegemiddelstyrelsen
DenmarkBravectoIntervet International B.V.1400 mgtyggetabletterCentralLaegemiddelstyrelsen
DenmarkBravectoIntervet International B.V.500 mgtyggetabletterCentralLaegemiddelstyrelsen
DenmarkBravecto til hunde >10-20 kgIntervet International B.V.500 mgspot-on, opløsningCentralLaegemiddelstyrelsen
European Union (EMA)Bravecto—AuthorisedEMA centrally authorised
European Union (EMA)Exzolt—AuthorisedEMA centrally authorised
European Union (EMA)Fluralaner Intervet—AuthorisedEMA centrally authorised
FinlandBravectoIntervet International B.V.1000 mgpurutablettiMyyntilupa myönnettyFimea Perusrekisteri
FinlandBravectoIntervet International B.V.112.5 mgpaikallisvaleluliuosMyyntilupa myönnettyFimea Perusrekisteri
FinlandBravectoIntervet International B.V.250 mgpurutablettiMyyntilupa myönnettyFimea Perusrekisteri
FinlandBravectoIntervet International B.V.500 mgpurutablettiMyyntilupa myönnettyFimea Perusrekisteri
FinlandBravectoIntervet International B.V.1400 mgpurutablettiMyyntilupa myönnettyFimea Perusrekisteri
FinlandBravectoIntervet International B.V.250 mgpaikallisvaleluliuosMyyntilupa myönnettyFimea Perusrekisteri
FinlandBravectoIntervet International B.V.500 mgpaikallisvaleluliuosMyyntilupa myönnettyFimea Perusrekisteri
Hong KongBravecto Chewable Tablets For Large Dogs 1000mg (Vet)Merck Sharp & Dohme (Asia) LtdRegisteredDH Drug Office
Hong KongBravecto Chewable Tablets For Medium-Sized Dogs 500mg (Vet)Merck Sharp & Dohme (Asia) LtdRegisteredDH Drug Office
Hong KongBravecto Chewable Tablets For Small Dogs 250mg (Vet)Merck Sharp & Dohme (Asia) LtdRegisteredDH Drug Office
Hong KongBravecto Chewable Tablets For Very Large Dogs 1400mg (Vet)Merck Sharp & Dohme (Asia) LtdRegisteredDH Drug Office
Hong KongBravecto Chewable Tablets For Very Small Dogs 112.5mg (Vet)Merck Sharp & Dohme (Asia) LtdRegisteredDH Drug Office
IcelandBravectoIcepharma - óskráð500 mgtuggutfl0Lyfjastofnun lyfjaverdskra
MalaysiaExzolt 10mg/mL Solution For Use In Drinking Water For ChickensIntervet (m) Sdn BhdVeterinaryPRODUCT APPROVEDNPRA
PolandBravectoIntervet International B.V.1000 mgTabletki do żuciaURPL RPL
PolandExzoltIntervet International B.V.10 mg/mlRoztwór do podania w wodzie do piciaURPL RPL
United StatesFluralanerWisdom Pharmaceutical Co.,Ltd.PowderFDA NDC
United StatesFluralanerLivzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd.PowderFDA NDC
United StatesFluralanerNissan Chemical CorporationGranuleFDA NDC
United StatesFluralanerHisun Pharmaceutical (Nantong) Co., Ltd.PowderFDA NDC

See every manufacturer of Fluralaner worldwide →

Regulator price references for Fluralaner

Published list or reimbursement prices for Fluralaner presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.

CountryProductStrengthPackPriceTypeSourceAs of
IcelandBravecto500mgpakki8,300.00 ISKmax wholesaleLyfjastofnun lyfjaverdskra2026-09-02

Marketed Canadian products with the same active ingredient

DINProductCompanyStrengthForm
02502216Bravecto OneIntervet Canada Corp45 mgTablet (Chewable)
02502232Bravecto OneIntervet Canada Corp200 mgTablet (Chewable)
02502240Bravecto OneIntervet Canada Corp400 mgTablet (Chewable)

Sourcing through Nexara Health

Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.

Frequently asked questions

Is Bravecto One (DIN 02502224) marketed in Canada?

Yes. Health Canada lists DIN 02502224 as Marketed as of 05 Apr 2021.

Who holds the Canadian licence for this product?

Intervet Canada Corp is the company of record in the Health Canada Drug Product Database.

Is Fluralaner registered outside Canada?

Yes — Nexara Health has matched 57 registrations in 8 other markets, including 3 in the same strength and dosage form (see the table above).

Where does this data come from?

Health Canada Drug Product Database (DPD), DIN 02502224, status date 2021-04-05; national medicine registries: DH Drug Office, EMA centrally authorised, FDA NDC, Fimea Perusrekisteri, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, NPRA, URPL RPL; price sources: Lyfjastofnun lyfjaverdskra. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.

Source: Health Canada Drug Product Database (DPD), DIN 02502224, status date 2021-04-05; national medicine registries: DH Drug Office, EMA centrally authorised, FDA NDC, Fimea Perusrekisteri, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, NPRA, URPL RPL; price sources: Lyfjastofnun lyfjaverdskra.

Health Canada Drug Product Database (DPD), DIN 02502224, status date 2021-04-05; national medicine registries: DH Drug Office, EMA centrally authorised, FDA NDC, Fimea Perusrekisteri, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, NPRA, URPL RPL; price sources: Lyfjastofnun lyfjaverdskra. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.